Basf withdraws from the purchase of Evonik after the rejection of its two offers

Basf abandons the purchase of Evonik after its rejection of its two bids, despite having raised the offer to above 11,000 million euros.

fotonoticia 20261119170028 1920

fotonoticia 20261119170028 1920

Add DEMÓCRATA to Google

Ask FREN

Published

1 minute

Most read

Elecciones 29N · Encuestas

La media de las encuestas

Media a 19 de noviembre de 2026 · 18 institutos

  • PP31,1 %
  • PSOE27,4 %
  • Vox19,1 %
  • Frente Amplio6,2 %
  • ERC2,5 %
01020304050ene 2024jul 2024ene 2025jul 2025ene 2026jul 2026

Media del último estudio de cada instituto en 30 días y su evolución semanal desde el 23J. Partidos con al menos un 2 %.

Todas las encuestas

Elecciones generales del 29 de noviembre · Demócrata

The German chemical group Basf has announced that it definitively abandons its plan to acquire its competitor Evonik, also based in Germany, after several weeks of overtures in which the target company rejected its purchase proposals on two occasions.

"Despite the fact that Basf indicated that it was willing to consider a moderate increase in its offer, Evonik's board of directors has not shown significant interest to date," a company statement says.

The multinational has pointed out that, after reviewing in detail Evonik's outlook as an independent company and the risks linked to its future development, it sees no justification for giving it a higher valuation. At the same time, it has determined that moving forward with the transaction would not be favorable to the interests of its own shareholders.

"We are convinced that Basf's offer, fully in cash and with reduced risk, of 24 euros per share, would have represented significant added value for Evonik shareholders. We continue to believe that the merger would create a more powerful chemical company under Basf's ownership, generating additional value for shareholders, as well as benefits for the employees and customers of the resulting entity," Basf board chairman Markus Kamieth said.

Basf has emphasized that corporate transactions are "a viable option, not an obligation" to strengthen its key business areas. With the withdrawal of its offer by Evonik, the company intends to underline its commitment to a "disciplined" capital allocation and to maintaining an "attractive" dividend policy for its investors.

At the end of October, Basf had increased the amount of its proposed acquisition of Evonik, raising it above 11,000 million euros, compared with the 10.3 billion euros initially proposed and rejected by the other party. The revised offer included the payment of 24 euros for each Evonik share.

After Basf's withdrawal became known, Evonik shares have fallen by more than 16%, practically wiping out the progress made in September, when the first negotiations about the possible transaction came to light. The shares traded at 18.26 euros, down from 21.78 euros at the start of the session, and clearly below the 24 euros offered in the offer.